Selexis leadership planning for active line up of speaking engagements, partnering and exhibit activities, and sponsorships
Geneva, Switzerland, 30 March 2016 – Selexis SA, a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, announced today its planned participation at several conferences this Spring, as follows:
BIO-Europe Spring® 2016
4 - 6 April 2016, Berzelii Park, Stockholm, Sweden
Selexis Chief Executive Officer and Chairman Igor Fisch, PhD, will participate in a panel discussion entitled “The Alliance Manager: Bridging the Culture Gap,” on 4 April at 2:45 p.m. CET. Selexis will also be participating in the partnering program.
For more information visit: http://www.ebdgroup.com/bes
Cell Line Development & Engineering
11 - 13 April 2016, Reed Messe Wien Congress Center, Vienna, Austria
Selexis Scientific Founder, Board Member and Scientific Advisor Nicolas Mermod, PhD, University of Lausanne, will present on 12 April at 4:05 p.m. CET during the Selection Strategies session on “Implementing Next Generation Sequencing in Routine Cell Line Development.” Selexis is also a sponsor and exhibitor.
For more information visit: http://www.informa-ls.com/event/CellLine16
12th Annual PEGS Boston: The Essential Protein Engineering Summit
25 - 29 April 2016, Seaport World Trade Center, Boston, Massachusetts, USA
Selexis Chief Scientific Officer Pierre-Alain Girod, PhD, will present on 27 April at 12:25 p.m. EST during the Optimizing Antibody Selection and Screening session on “Analysis of the Genomics and Transcriptomics of CHO-K1 to Accelerate and De-risk Biologics Development.”?Selexis is also a sponsor and exhibitor.
For more information visit: http://www.pegsummit.com/
2016 BIO International Convention
6 - 9 June 2016, Moscone Center, San Francisco, California, USA
Selexis will be participating in the partnering program and is also an exhibitor.
For more Information visit: http://convention.bio.org/2016/
About Selexis SA
Selexis SA is a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, providing unparalleled proprietary technology and the highly specialized expertise that is necessary to translate scientific innovation into life-saving medicines for patients. Selexis’s SUREtechnology Platform™ facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the bioproduction continuum, spanning discovery to commercialization. With nearly 90 clients worldwide and more than 65 drug products in clinical and commercial manufacturing utilizing its cell lines, Selexis has a history of empowering scientists and biopharmaceutical companies around the world to realize the full potential of their research.
FOR MORE INFORMATION
- Web www.selexis.com
- LinkedIn www.linkedin.com/company/selexis-sa
- Twitter www.twitter.com/SelexisSA
- Facebook www.facebook.com/SelexisSA
Media Inquires for Selexis
Mike Beyer
Sam Brown Inc.
+1 312-961-2502
mikebeyer@sambrown.com
Company Inquiries for Selexis
Robert Meister
Head, Corporate Communications
Tel. +1 602 953 1716
robert.meister@selexis.com
